Click for best price
Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size, Share 2024
| Market size in 2023 |
US$ 351.9 million
|
Forecast Market size by 2030 |
US$ 568.1 million
|
| Growth Rate |
CAGR of 7.1% |
Number of Pages |
72 Pages |
The global Inactivated Vaccine for Swine Mycoplasma Pneumonia market was valued at US$ 351.9 million in 2023 and is projected to reach US$ 568.1 million by 2030, at a CAGR of 7.1% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2023, While China is Forecast to Reach $ Million.
Single Vaccine Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Inactivated Vaccine for Swine Mycoplasma Pneumonia include Zoetis, Boehringer Ingelheim, Jinhe Biotechnology, Merck, HIPRA, Ceva Sant? Animale, Harbin Pharmaceutical Group, Pulike Biotech and Qilu Animal Health Products, etc. in 2023, the global top five players have a share approximately % in terms of revenue.
Inactivated vaccines for Swine Mycoplasma pneumonia are also available. They are made by using inactivated or killed strains of the bacteria to stimulate an immune response in pigs without causing disease.
This report aims to provide a comprehensive presentation of the global market for Inactivated Vaccine for Swine Mycoplasma Pneumonia, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Inactivated Vaccine for Swine Mycoplasma Pneumonia. This report contains market size and forecasts of Inactivated Vaccine for Swine Mycoplasma Pneumonia in global, including the following market information:
- Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Revenue, 2019-2024, 2025-2030, ($ millions)
- Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Sales, 2019-2024, 2025-2030, (K Units)
- Global top five Inactivated Vaccine for Swine Mycoplasma Pneumonia companies in 2023 (%)
We surveyed the Inactivated Vaccine for Swine Mycoplasma Pneumonia manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market, by Type, 2019-2024, 2025-2030 ($ Millions) & (K Units)
Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Segment Percentages, by Type, 2023 (%)
- Single Vaccine
- Dual Vaccine
Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market, by Application, 2019-2024, 2025-2030 ($ Millions) & (K Units)
Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Segment Percentages, by Application, 2023 (%)
Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market, By Region and Country, 2019-2024, 2025-2030 ($ Millions) & (K Units)
Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Segment Percentages, By Region and Country, 2023 (%)
- North America (United States, Canada, Mexico)
- Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe)
- Asia-Pacific (China, India, Japan, South Korea, Australia, Rest of APAC)
- The Middle East and Africa (Middle East, Africa)
- South and Central America (Brazil, Argentina, Rest of SCA)
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Inactivated Vaccine for Swine Mycoplasma Pneumonia revenues in global market, 2019-2024 (Estimated), ($ millions)
- Key companies Inactivated Vaccine for Swine Mycoplasma Pneumonia revenues share in global market, 2023 (%)
- Key companies Inactivated Vaccine for Swine Mycoplasma Pneumonia sales in global market, 2019-2024 (Estimated), (K Units)
- Key companies Inactivated Vaccine for Swine Mycoplasma Pneumonia sales share in global market, 2023 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Zoetis
- Boehringer Ingelheim
- Jinhe Biotechnology
- Merck
- HIPRA
- Ceva Sant? Animale
- Harbin Pharmaceutical Group
- Pulike Biotech
- Qilu Animal Health Products
- Wuhan Keqian Biology
Outline of Major Chapters:
Chapter 1: Introduces the definition of Inactivated Vaccine for Swine Mycoplasma Pneumonia, market overview.
Chapter 2: Global Inactivated Vaccine for Swine Mycoplasma Pneumonia market size in revenue and volume.
Chapter 3: Detailed analysis of Inactivated Vaccine for Swine Mycoplasma Pneumonia manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Inactivated Vaccine for Swine Mycoplasma Pneumonia in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Inactivated Vaccine for Swine Mycoplasma Pneumonia capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Inactivated Vaccine for Swine Mycoplasma Pneumonia Market, Global Outlook and Forecast 2024-2030 |
| Market size in 2023 |
US$ 351.9 million
|
| Forecast Market size by 2030 |
US$ 568.1 million
|
| Growth Rate |
CAGR of 7.1% |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2023 |
| Forecast Year |
2031 |
| Number of Pages |
72 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Overall Market Size
2.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size: 2023 VS 2030
2.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, Prospects & Forecasts: 2019-2030
2.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales: 2019-2030
3 Company Landscape
3.1 Top Inactivated Vaccine for Swine Mycoplasma Pneumonia Players in Global Market
3.2 Top Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Companies Ranked by Revenue
3.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue by Companies
3.4 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Companies
3.5 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Price by Manufacturer (2019-2024)
3.6 Top 3 and Top 5 Inactivated Vaccine for Swine Mycoplasma Pneumonia Companies in Global Market, by Revenue in 2023
3.7 Global Manufacturers Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Type
3.8 Tier 1, Tier 2 and Tier 3 Inactivated Vaccine for Swine Mycoplasma Pneumonia Players in Global Market
3.8.1 List of Global Tier 1 Inactivated Vaccine for Swine Mycoplasma Pneumonia Companies
3.8.2 List of Global Tier 2 and Tier 3 Inactivated Vaccine for Swine Mycoplasma Pneumonia Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Markets, 2023 & 2030
4.1.2 Single Vaccine
4.1.3 Dual Vaccine
4.2 By Type - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue & Forecasts
4.2.1 By Type - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, 2019-2024
4.2.2 By Type - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, 2025-2030
4.2.3 By Type - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue Market Share, 2019-2030
4.3 By Type - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales & Forecasts
4.3.1 By Type - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales, 2019-2024
4.3.2 By Type - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales, 2025-2030
4.3.3 By Type - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share, 2019-2030
4.4 By Type - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Price (Manufacturers Selling Prices), 2019-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size, 2023 & 2030
5.1.2 Piglets
5.1.3 Adult Pigs
5.2 By Application - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue & Forecasts
5.2.1 By Application - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, 2019-2024
5.2.2 By Application - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, 2025-2030
5.2.3 By Application - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue Market Share, 2019-2030
5.3 By Application - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales & Forecasts
5.3.1 By Application - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales, 2019-2024
5.3.2 By Application - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales, 2025-2030
5.3.3 By Application - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share, 2019-2030
5.4 By Application - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Price (Manufacturers Selling Prices), 2019-2030
6 Sights by Region
6.1 By Region - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size, 2023 & 2030
6.2 By Region - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue & Forecasts
6.2.1 By Region - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, 2019-2024
6.2.2 By Region - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, 2025-2030
6.2.3 By Region - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue Market Share, 2019-2030
6.3 By Region - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales & Forecasts
6.3.1 By Region - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales, 2019-2024
6.3.2 By Region - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales, 2025-2030
6.3.3 By Region - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share, 2019-2030
6.4 North America
6.4.1 By Country - North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, 2019-2030
6.4.2 By Country - North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales, 2019-2030
6.4.3 US Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size, 2019-2030
6.4.4 Canada Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size, 2019-2030
6.4.5 Mexico Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size, 2019-2030
6.5 Europe
6.5.1 By Country - Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, 2019-2030
6.5.2 By Country - Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales, 2019-2030
6.5.3 Germany Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size, 2019-2030
6.5.4 France Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size, 2019-2030
6.5.5 U.K. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size, 2019-2030
6.5.6 Italy Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size, 2019-2030
6.5.7 Russia Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size, 2019-2030
6.5.8 Nordic Countries Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size, 2019-2030
6.5.9 Benelux Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size, 2019-2030
6.6 Asia
6.6.1 By Region - Asia Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, 2019-2030
6.6.2 By Region - Asia Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales, 2019-2030
6.6.3 China Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size, 2019-2030
6.6.4 Japan Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size, 2019-2030
6.6.5 South Korea Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size, 2019-2030
6.6.6 Southeast Asia Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size, 2019-2030
6.6.7 India Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size, 2019-2030
6.7 South America
6.7.1 By Country - South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, 2019-2030
6.7.2 By Country - South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales, 2019-2030
6.7.3 Brazil Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size, 2019-2030
6.7.4 Argentina Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size, 2019-2030
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, 2019-2030
6.8.2 By Country - Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales, 2019-2030
6.8.3 Turkey Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size, 2019-2030
6.8.4 Israel Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size, 2019-2030
6.8.5 Saudi Arabia Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size, 2019-2030
6.8.6 UAE Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size, 2019-2030
7 Manufacturers & Brands Profiles
7.1 Zoetis
7.1.1 Zoetis Company Summary
7.1.2 Zoetis Business Overview
7.1.3 Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Major Product Offerings
7.1.4 Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Revenue in Global (2019-2024)
7.1.5 Zoetis Key News & Latest Developments
7.2 Boehringer Ingelheim
7.2.1 Boehringer Ingelheim Company Summary
7.2.2 Boehringer Ingelheim Business Overview
7.2.3 Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Major Product Offerings
7.2.4 Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Revenue in Global (2019-2024)
7.2.5 Boehringer Ingelheim Key News & Latest Developments
7.3 Jinhe Biotechnology
7.3.1 Jinhe Biotechnology Company Summary
7.3.2 Jinhe Biotechnology Business Overview
7.3.3 Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Major Product Offerings
7.3.4 Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Revenue in Global (2019-2024)
7.3.5 Jinhe Biotechnology Key News & Latest Developments
7.4 Merck
7.4.1 Merck Company Summary
7.4.2 Merck Business Overview
7.4.3 Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Major Product Offerings
7.4.4 Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Revenue in Global (2019-2024)
7.4.5 Merck Key News & Latest Developments
7.5 HIPRA
7.5.1 HIPRA Company Summary
7.5.2 HIPRA Business Overview
7.5.3 HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Major Product Offerings
7.5.4 HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Revenue in Global (2019-2024)
7.5.5 HIPRA Key News & Latest Developments
7.6 Ceva Sant? Animale
7.6.1 Ceva Sant? Animale Company Summary
7.6.2 Ceva Sant? Animale Business Overview
7.6.3 Ceva Sant? Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Major Product Offerings
7.6.4 Ceva Sant? Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Revenue in Global (2019-2024)
7.6.5 Ceva Sant? Animale Key News & Latest Developments
7.7 Harbin Pharmaceutical Group
7.7.1 Harbin Pharmaceutical Group Company Summary
7.7.2 Harbin Pharmaceutical Group Business Overview
7.7.3 Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Major Product Offerings
7.7.4 Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Revenue in Global (2019-2024)
7.7.5 Harbin Pharmaceutical Group Key News & Latest Developments
7.8 Pulike Biotech
7.8.1 Pulike Biotech Company Summary
7.8.2 Pulike Biotech Business Overview
7.8.3 Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Major Product Offerings
7.8.4 Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Revenue in Global (2019-2024)
7.8.5 Pulike Biotech Key News & Latest Developments
7.9 Qilu Animal Health Products
7.9.1 Qilu Animal Health Products Company Summary
7.9.2 Qilu Animal Health Products Business Overview
7.9.3 Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Major Product Offerings
7.9.4 Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Revenue in Global (2019-2024)
7.9.5 Qilu Animal Health Products Key News & Latest Developments
7.10 Wuhan Keqian Biology
7.10.1 Wuhan Keqian Biology Company Summary
7.10.2 Wuhan Keqian Biology Business Overview
7.10.3 Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Major Product Offerings
7.10.4 Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Revenue in Global (2019-2024)
7.10.5 Wuhan Keqian Biology Key News & Latest Developments
8 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Capacity, Analysis
8.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Capacity, 2019-2030
8.2 Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Capacity of Key Manufacturers in Global Market
8.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Inactivated Vaccine for Swine Mycoplasma Pneumonia Supply Chain Analysis
10.1 Inactivated Vaccine for Swine Mycoplasma Pneumonia Industry Value Chain
10.2 Inactivated Vaccine for Swine Mycoplasma Pneumonia Upstream Market
10.3 Inactivated Vaccine for Swine Mycoplasma Pneumonia Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Inactivated Vaccine for Swine Mycoplasma Pneumonia Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Inactivated Vaccine for Swine Mycoplasma Pneumonia in Global Market
Table 2. Top Inactivated Vaccine for Swine Mycoplasma Pneumonia Players in Global Market, Ranking by Revenue (2023)
Table 3. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue by Companies, (US$, Mn), 2019-2024
Table 4. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue Share by Companies, 2019-2024
Table 5. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Companies, (K Units), 2019-2024
Table 6. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Share by Companies, 2019-2024
Table 7. Key Manufacturers Inactivated Vaccine for Swine Mycoplasma Pneumonia Price (2019-2024) & (US$/Unit)
Table 8. Global Manufacturers Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Type
Table 9. List of Global Tier 1 Inactivated Vaccine for Swine Mycoplasma Pneumonia Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Inactivated Vaccine for Swine Mycoplasma Pneumonia Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 11. By Type ? Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, (US$, Mn), 2023 & 2030
Table 12. By Type - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue (US$, Mn), 2019-2024
Table 13. By Type - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue (US$, Mn), 2025-2030
Table 14. By Type - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K Units), 2019-2024
Table 15. By Type - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K Units), 2025-2030
Table 16. By Application ? Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, (US$, Mn), 2023 & 2030
Table 17. By Application - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue (US$, Mn), 2019-2024
Table 18. By Application - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue (US$, Mn), 2025-2030
Table 19. By Application - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K Units), 2019-2024
Table 20. By Application - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K Units), 2025-2030
Table 21. By Region ? Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, (US$, Mn), 2023 VS 2030
Table 22. By Region - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue (US$, Mn), 2019-2024
Table 23. By Region - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue (US$, Mn), 2025-2030
Table 24. By Region - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K Units), 2019-2024
Table 25. By Region - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K Units), 2025-2030
Table 26. By Country - North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, (US$, Mn), 2019-2024
Table 27. By Country - North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, (US$, Mn), 2025-2030
Table 28. By Country - North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales, (K Units), 2019-2024
Table 29. By Country - North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales, (K Units), 2025-2030
Table 30. By Country - Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, (US$, Mn), 2019-2024
Table 31. By Country - Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, (US$, Mn), 2025-2030
Table 32. By Country - Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales, (K Units), 2019-2024
Table 33. By Country - Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales, (K Units), 2025-2030
Table 34. By Region - Asia Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, (US$, Mn), 2019-2024
Table 35. By Region - Asia Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, (US$, Mn), 2025-2030
Table 36. By Region - Asia Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales, (K Units), 2019-2024
Table 37. By Region - Asia Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales, (K Units), 2025-2030
Table 38. By Country - South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, (US$, Mn), 2019-2024
Table 39. By Country - South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, (US$, Mn), 2025-2030
Table 40. By Country - South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales, (K Units), 2019-2024
Table 41. By Country - South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales, (K Units), 2025-2030
Table 42. By Country - Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, (US$, Mn), 2019-2024
Table 43. By Country - Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, (US$, Mn), 2025-2030
Table 44. By Country - Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales, (K Units), 2019-2024
Table 45. By Country - Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales, (K Units), 2025-2030
Table 46. Zoetis Company Summary
Table 47. Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
Table 48. Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2019-2024)
Table 49. Zoetis Key News & Latest Developments
Table 50. Boehringer Ingelheim Company Summary
Table 51. Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
Table 52. Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2019-2024)
Table 53. Boehringer Ingelheim Key News & Latest Developments
Table 54. Jinhe Biotechnology Company Summary
Table 55. Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
Table 56. Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2019-2024)
Table 57. Jinhe Biotechnology Key News & Latest Developments
Table 58. Merck Company Summary
Table 59. Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
Table 60. Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2019-2024)
Table 61. Merck Key News & Latest Developments
Table 62. HIPRA Company Summary
Table 63. HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
Table 64. HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2019-2024)
Table 65. HIPRA Key News & Latest Developments
Table 66. Ceva Sant? Animale Company Summary
Table 67. Ceva Sant? Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
Table 68. Ceva Sant? Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2019-2024)
Table 69. Ceva Sant? Animale Key News & Latest Developments
Table 70. Harbin Pharmaceutical Group Company Summary
Table 71. Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
Table 72. Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2019-2024)
Table 73. Harbin Pharmaceutical Group Key News & Latest Developments
Table 74. Pulike Biotech Company Summary
Table 75. Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
Table 76. Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2019-2024)
Table 77. Pulike Biotech Key News & Latest Developments
Table 78. Qilu Animal Health Products Company Summary
Table 79. Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
Table 80. Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2019-2024)
Table 81. Qilu Animal Health Products Key News & Latest Developments
Table 82. Wuhan Keqian Biology Company Summary
Table 83. Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
Table 84. Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2019-2024)
Table 85. Wuhan Keqian Biology Key News & Latest Developments
Table 86. Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2024 (K Units)
Table 87. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Capacity Market Share of Key Manufacturers, 2021-2024
Table 88. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production by Region, 2019-2024 (K Units)
Table 89. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production by Region, 2025-2030 (K Units)
Table 90. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Opportunities & Trends in Global Market
Table 91. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Drivers in Global Market
Table 92. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Restraints in Global Market
Table 93. Inactivated Vaccine for Swine Mycoplasma Pneumonia Raw Materials
Table 94. Inactivated Vaccine for Swine Mycoplasma Pneumonia Raw Materials Suppliers in Global Market
Table 95. Typical Inactivated Vaccine for Swine Mycoplasma Pneumonia Downstream
Table 96. Inactivated Vaccine for Swine Mycoplasma Pneumonia Downstream Clients in Global Market
Table 97. Inactivated Vaccine for Swine Mycoplasma Pneumonia Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Inactivated Vaccine for Swine Mycoplasma Pneumonia Segment by Type in 2023
Figure 2. Inactivated Vaccine for Swine Mycoplasma Pneumonia Segment by Application in 2023
Figure 3. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Overview: 2023
Figure 4. Key Caveats
Figure 5. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size: 2023 VS 2030 (US$, Mn)
Figure 6. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, 2019-2030 (US$, Mn)
Figure 7. Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales in Global Market: 2019-2030 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue in 2023
Figure 9. By Type - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, (US$, Mn), 2023 & 2030
Figure 10. By Type - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue Market Share, 2019-2030
Figure 11. By Type - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share, 2019-2030
Figure 12. By Type - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Price (US$/Unit), 2019-2030
Figure 13. By Application - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, (US$, Mn), 2023 & 2030
Figure 14. By Application - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue Market Share, 2019-2030
Figure 15. By Application - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share, 2019-2030
Figure 16. By Application - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Price (US$/Unit), 2019-2030
Figure 17. By Region - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, (US$, Mn), 2023 & 2030
Figure 18. By Region - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue Market Share, 2019 VS 2023 VS 2030
Figure 19. By Region - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue Market Share, 2019-2030
Figure 20. By Region - Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share, 2019-2030
Figure 21. By Country - North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue Market Share, 2019-2030
Figure 22. By Country - North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share, 2019-2030
Figure 23. US Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, (US$, Mn), 2019-2030
Figure 24. Canada Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, (US$, Mn), 2019-2030
Figure 25. Mexico Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, (US$, Mn), 2019-2030
Figure 26. By Country - Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue Market Share, 2019-2030
Figure 27. By Country - Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share, 2019-2030
Figure 28. Germany Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, (US$, Mn), 2019-2030
Figure 29. France Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, (US$, Mn), 2019-2030
Figure 30. U.K. Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, (US$, Mn), 2019-2030
Figure 31. Italy Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, (US$, Mn), 2019-2030
Figure 32. Russia Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, (US$, Mn), 2019-2030
Figure 33. Nordic Countries Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, (US$, Mn), 2019-2030
Figure 34. Benelux Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, (US$, Mn), 2019-2030
Figure 35. By Region - Asia Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue Market Share, 2019-2030
Figure 36. By Region - Asia Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share, 2019-2030
Figure 37. China Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, (US$, Mn), 2019-2030
Figure 38. Japan Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, (US$, Mn), 2019-2030
Figure 39. South Korea Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, (US$, Mn), 2019-2030
Figure 40. Southeast Asia Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, (US$, Mn), 2019-2030
Figure 41. India Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, (US$, Mn), 2019-2030
Figure 42. By Country - South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue Market Share, 2019-2030
Figure 43. By Country - South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share, 2019-2030
Figure 44. Brazil Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, (US$, Mn), 2019-2030
Figure 45. Argentina Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, (US$, Mn), 2019-2030
Figure 46. By Country - Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue Market Share, 2019-2030
Figure 47. By Country - Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share, 2019-2030
Figure 48. Turkey Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, (US$, Mn), 2019-2030
Figure 49. Israel Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, (US$, Mn), 2019-2030
Figure 50. Saudi Arabia Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, (US$, Mn), 2019-2030
Figure 51. UAE Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue, (US$, Mn), 2019-2030
Figure 52. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Capacity (K Units), 2019-2030
Figure 53. The Percentage of Production Inactivated Vaccine for Swine Mycoplasma Pneumonia by Region, 2023 VS 2030
Figure 54. Inactivated Vaccine for Swine Mycoplasma Pneumonia Industry Value Chain
Figure 55. Marketing Channels
